Nutriband (NASDAQ:NTRB) versus CDT Equity (NASDAQ:CDT) Financial Contrast

Nutriband (NASDAQ:NTRB) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for Nutriband and CDT Equity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
CDT Equity	1	0	0	0	1.00

Profitability

This table compares Nutriband and CDT Equity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
CDT Equity	N/A	-145.29%	-103.25%

Insider & Institutional Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Nutriband and CDT Equity”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04 million	18.54	-$8.23 million	($2.58)	-1.21
CDT Equity	N/A	N/A	-$39.22 million	($5,379.02)	-0.00

Nutriband has higher revenue and earnings than CDT Equity. Nutriband is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nutriband has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Summary

Nutriband beats CDT Equity on 9 of the 11 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.